Ruplizumab

Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) [1][2].

Product Specifications

CAS Number

[220651-94-5]

Product Name Alternative

BG 9588; Anti-Human CD40L Recombinant Antibody; Hu5c8

UNSPSC

12352203

Target

TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ruplizumab.html

Purity

99.84

Solubility

10 mM in DMSO

Smiles

[Ruplizumab]

Molecular Weight

(145.68 kDa)

References & Citations

[1]Chris Chamberlain, et al. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles. Ann Rheum Dis. 2017 Nov;76 (11) :1837-1844.|[2]Law C L, et al. Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges. Therapeutic targets of the TNF superfamily, 2009: 8-36.